Letairis is a brand name of ambrisentan, approved by the FDA in the following formulation(s):
LETAIRIS (ambrisentan - tablet; oral)
Manufacturer: GILEAD
Approval date: June 15, 2007
Strength(s): 10MG [RLD], 5MG
Has a generic version of Letairis been approved?
No. There is currently no therapeutically equivalent version of Letairis available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Letairis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation
Patent 5,703,017
Issued: December 30, 1997
Inventor(s): Baumann; Ernst & Rheinheimer; Joachim & Vogelbacher; Uwe Josef & Bratz; Matthias & Theobald; Hans & Gerber; Matthias & Westphalen; Karl-Otto & Walter; Helmut & Rademacher; Wilhelm
Assignee(s): BASF Aktiengesellschaft
3-(Het)arylcarboxylic acid derivatives of the formula I ##STR1## where R is formyl, CO.sub.2 H or a radical hydrolyzable to COOH and the other substituents have the following meanings: R.sup.2 and R.sup.3 are each halogen, alkyl, haloalkyl, alkoxy, haloalkoxy or alkylthio; X is nitrogen or CR.sup.14, where R.sup.14 is hydrogen or, together with R.sup.3, forms an alkylene or alkenylene chain, in each of which a methylene group is replaced by oxygen; R.sup.4 is phenyl or naphthyl, each of which is unsubstituted or substituted or an unsubstituted or substituted five-membered or six-membered heteroaromatic structure containing one to three nitrogen atoms or one sulfur or oxygen atom; R.sup.5 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, alkoxyalkyl, alkylthioalkyl or phenyl; R.sup.6 is C.sub.1 -C.sub.8 -alkyl, C.sub.3 -C.sub.6 -alkenyl, C.sub.3 -C.sub.6 -alkynyl or C.sub.3 -C.sub.4 -cyclo-alkyl, each of which may be mono- or polysubstituted; Y is sulfur, oxygen or a single bond; and Z is sulfur or oxygen; with the proviso that R.sup.6 is not unsubstituted C.sub.1 -C.sub.4 -alkyl when R.sup.4 is unsubstituted phenyl, Z is oxygen and simultaneously R.sup.5 is methyl or hydrogen.Patent expiration dates:
- December 30, 2014✓
- December 30, 2014
Use of carboxylic acid derivatives as drugs
Patent 5,840,722
Issued: November 24, 1998
Inventor(s): Baumann; Ernst & Vogelbacher; Uwe Josef & Rheinheimer; Joachim & Klinge; Dagmar & Riechers; Hartmut & Kroger; Burkhard & Bialojan; Siegfried & Bollschweiler; Claus & Wernet; Wolfgang & Unger; Liliane & Raschack; Manfred
Assignee(s): BASF Aktiengesellschaft
A method of inhibiting endothelin receptors by administering to a patient a compound of the formula I ##STR1##Patent expiration dates:
- November 24, 2015✓
- November 24, 2015
Carboxylic acid derivatives, their preparation and use
Patent 7,109,205
Issued: September 19, 2006
Inventor(s): Riechers; Hartmut & Klinge; Dagmar & Amberg; Wilhelm & Kling; Andreas & Müller; Stefan & Baumann; Ernst & Rheinheimer; Joachim & Vogelbacher; Uwe Josef & Wernet; Wolfgang & Unger; Liliane & Raschack; Manfred
Assignee(s): Abbott GmbH & Co. KG
Carboxylic acid derivatives where R–R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.Patent expiration dates:
- October 7, 2015✓✓
- October 7, 2015
Carboxylic acid derivatives, their preparation and use
Patent 7,601,730
Issued: October 13, 2009
Inventor(s): Riechers; Hartmut & Klinge; Dagmar & Amberg; Wilhelm & Kling; Andreas & Muller; Stefan & Baumann; Ernst & Rheinheimer; Joachim & Vogelbacher; Uwe Josef & Wernet; Wolfgang & Unger; Liliane & Raschack; Manfred
Assignee(s): Abbott GmbH & Co. KG
Carboxylic acid derivatives where R—R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.Patent expiration dates:
- October 7, 2015✓
- October 7, 2015
Carboxylic acid derivatives, their preparation and use
Patent RE42462
Issued: June 14, 2011
Inventor(s): Riechers; Hartmut & Klinge; Dagmar & Amberg; Wilhelm & Kling; Andreas & Muller; Stefan & Baumann; Ernst & Rheinheimer; Joachim & Vogelbacher; Uwe Josef & Wernet; Wolfgang & Unger; Liliane & Raschack; Manfred
Assignee(s): Abbott GmbH & Co. KG
Carboxylic acid derivatives where R-R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.Patent expiration dates:
- October 7, 2015✓
- October 7, 2015
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- June 15, 2012 - NEW CHEMICAL ENTITY
- June 15, 2014 - ORPHAN DRUG EXCLUSIVITY
See also...
- Letairis Consumer Information (Drugs.com)
- Letairis Consumer Information (Wolters Kluwer)
- Letairis Consumer Information (Cerner Multum)
- Letairis Advanced Consumer Information (Micromedex)
- Letairis AHFS DI Monographs (ASHP)
- Ambrisentan Consumer Information (Wolters Kluwer)
- Ambrisentan Consumer Information (Cerner Multum)
- Ambrisentan Advanced Consumer Information (Micromedex)
- Ambrisentan AHFS DI Monographs (ASHP)
No comments:
Post a Comment